Phase 3 Study of Olaparib in Metastatic Colorectal Cancer Patients

A Phase 3 Randomized, Open-label Study to Evaluate the Efficacy and Safety of Olaparib Alone or in Combination With Bevacizumab Compared to Bevacizumab With 5-FU in Participants with Unresectable or Metastatic Colorectal Cancer who Have not Progressed Following First-line Induction of FOLFOX With Bevacizumab

Disease Types: Colon

Available at: Alleghany, Blacksburg, Roanoke, Salem, Wytheville

A Phase 3 Randomized, Open-label Study to Evaluate the Efficacy and Safety of Olaparib Alone or in Combination With Bevacizumab Compared to Bevacizumab With 5-FU in Participants with Unresectable or Metastatic Colorectal Cancer who Have not Progressed Following First-line Induction of FOLFOX With Bevacizumab

For more information:

https://clinicaltrials.gov/ct2/show/NCT04456699?term=MK7339-003&draw=2&rank=1